Biased Ligands. Better Drugs.

Trevena, Inc. (NASDAQ: TRVN) is a clinical stage biopharmaceutical company focused on discovering and developing biased ligands to deliver the next generation of GPCR targeted medicines

We have identified three product candidates as potential best-in-class or first-in-class therapies for patients suffering from serious unmet medical needs.

Copyright © Trevena, Inc.